CureVac SE

CureVac and MD Anderson Partner to Develop Cancer Vaccines

Biopharmaceutical company CureVac has announced a co-development and licensing agreement with The University of Texas MD Anderson Cancer Center to develop novel mRNA-based cancer vaccines.